Edarbi Shortage: What Providers and Prescribers Need to Know in 2026

As a provider prescribing Edarbi (Azilsartan Medoxomil) for hypertension management, you may have heard from patients struggling to fill their prescriptions. While Edarbi is not currently on the FDA's formal drug shortage list, real-world availability challenges persist — and they're affecting patient adherence and clinical outcomes.

This briefing covers the current state of Edarbi supply, the factors driving availability issues, prescribing considerations, and practical tools to help your patients maintain consistent access to their blood pressure medication.

Timeline: How We Got Here

Edarbi (Azilsartan Medoxomil) was developed by Takeda Pharmaceuticals and received FDA approval in February 2011 as the eighth ARB to enter the U.S. market. It was positioned as a more potent option for blood pressure reduction compared to other ARBs like Olmesartan and Valsartan, based on pivotal clinical trial data involving over 5,900 patients.

Key milestones:

• 2011: FDA approval of Edarbi 40 mg and 80 mg tablets
• 2011: Edarbyclor (Azilsartan/Chlorthalidone combination) approved
• 2013: Takeda licenses U.S. commercialization rights to Arbor Pharmaceuticals
• 2022: FDA approves an abbreviated new drug application (ANDA) for generic Azilsartan Medoxomil, but patent protections prevent market entry
• 2024-present: Azurity Pharmaceuticals markets Edarbi; no generic version reaches pharmacies

The persistent absence of a generic alternative is the primary driver of both cost and availability challenges.

Prescribing Implications

Clinical Considerations

Edarbi demonstrated superior blood pressure reduction compared to Olmesartan 40 mg and Valsartan 320 mg in head-to-head clinical trials. For patients who have not achieved target blood pressure on other ARBs, Edarbi may represent a clinically meaningful option.

However, the practical barriers to access must be weighed against clinical benefit:

• Adherence risk: Patients who cannot consistently fill their Edarbi prescription face gaps in treatment, which increases cardiovascular event risk
• Cost burden: At $294 to $376 per month without insurance, financial toxicity is a real concern, particularly for uninsured or underinsured patients
• Step therapy delays: Many payers require trial of generic ARBs before authorizing Edarbi, which can delay optimal therapy by weeks

When to Prescribe Edarbi

Consider Edarbi for patients who:

• Have not achieved adequate blood pressure control on maximally dosed generic ARBs
• Have documented tolerability issues with other ARBs
• Have commercial insurance with access to the manufacturer copay program (reducing cost to $15/month)
• Can reliably access the medication (confirmed pharmacy availability)

When to Consider Alternatives

A switch to a generic ARB may be more appropriate when:

• The patient is uninsured or has a high-deductible plan without copay card eligibility
• The patient reports consistent difficulty finding Edarbi in stock
• Formulary restrictions create recurring prior authorization burdens
• Adherence is compromised by access barriers

For clinical comparison data on ARB alternatives, see our provider resource on helping patients find Edarbi.

The Availability Picture

Edarbi is not listed on the FDA Drug Shortage Database as of March 2026. The manufacturer, Azurity Pharmaceuticals, has not reported a supply disruption.

However, practical availability is limited by:

• Low pharmacy stocking: Chain pharmacies (CVS, Walgreens, Rite Aid) may not routinely stock Edarbi due to low prescription volume relative to generic ARBs
• Single-source supply: With no generic on the market, all supply comes from Azurity Pharmaceuticals
• Regional variability: Wholesaler distribution patterns create geographic pockets where Edarbi is readily available and others where it is consistently difficult to source
• Ordering delays: Pharmacies that don't stock Edarbi can typically special-order it within 1-2 business days, but this requires patient awareness and pharmacist initiative

Cost and Access Overview

The Azurity Solutions E-Z Rx Program offers a copay savings card for commercially insured patients, reducing out-of-pocket cost to as little as $15 per 30-day supply. This card is not available for patients on Medicare, Medicaid, Tricare, or other government-funded insurance.

For patients who cannot access the copay program, additional resources include:

• NeedyMeds (needymeds.org)
• RxAssist (rxassist.org)
• Pharmacy discount cards (GoodRx, SingleCare)

See our patient-facing resource on saving money on Edarbi for details you can share with patients, and our provider-focused guide on helping patients save on Edarbi.

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers is a free tool that helps clinical teams locate pharmacies with Edarbi in stock. You can direct patients to check availability before leaving the office, or use it during the prescribing workflow to confirm that the medication can be filled locally.

Pharmacy Coordination

When prescribing Edarbi, consider these workflow enhancements:

• Confirm stock before sending the prescription — Use Medfinder or have staff call the pharmacy to verify Edarbi availability
• Prescribe to pharmacies that stock it — If the patient's usual pharmacy doesn't carry Edarbi, route the prescription to one that does
• Include DAW (Dispense As Written) when appropriate — If the patient has specifically responded well to Edarbi and you want to prevent substitution
• Write for 90-day supplies — Reduces refill frequency and gives patients and pharmacies more planning time

Prior Authorization Support

When payer step therapy or prior authorization is required, document:

• Previous ARB trials and inadequate response
• Tolerability issues with generic alternatives
• Clinical rationale for Edarbi specifically (e.g., superior blood pressure reduction in clinical trials)

Looking Ahead

The key factors that could change the Edarbi landscape in the near term:

• Generic market entry: If patent challenges are resolved, generic Azilsartan Medoxomil could significantly improve availability and reduce cost
• Formulary changes: Payer decisions about Edarbi tier placement and step therapy requirements will continue to influence access
• Manufacturer supply: Any changes in Azurity Pharmaceuticals' production or distribution could affect availability either positively or negatively

We will update this article as new developments emerge.

Final Thoughts

Edarbi remains a clinically valuable ARB option for hypertension management, particularly for patients who have not achieved target blood pressure on other agents. However, the combination of single-source supply, absent generic competition, and payer restrictions creates meaningful access barriers that affect prescribing decisions and patient outcomes.

Providers can mitigate these challenges by confirming pharmacy stock before prescribing, leveraging the manufacturer copay program for eligible patients, maintaining familiarity with generic ARB alternatives, and using tools like Medfinder for Providers to streamline the process.

The goal is simple: ensure every patient who needs consistent blood pressure control can actually get their medication.